BioXcel Therapeutics Announced Preliminary Sales Of Igalmi (Dexmedetomidine) Sublingual Film For Q2 Of Approximately $1.1M, Up Approximately 90% Quarter Over Quarter And Approximately 141% Year-over-year
Portfolio Pulse from Benzinga Newsdesk
BioXcel Therapeutics announced preliminary Q2 sales of Igalmi (Dexmedetomidine) sublingual film at approximately $1.1M, marking a 90% increase quarter-over-quarter and a 141% increase year-over-year.
July 16, 2024 | 11:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioXcel Therapeutics reported significant growth in Q2 sales of Igalmi, with a 90% increase quarter-over-quarter and a 141% increase year-over-year, indicating strong market adoption and potential for continued revenue growth.
The significant increase in sales of Igalmi suggests strong market adoption and potential for continued revenue growth, which is likely to positively impact BioXcel Therapeutics' stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100